Clinical trials of a new anthelmintic, 4-isothiocyanato-4'-nitrodiphenylamine (C.9333-Go/CGP 4540), for the cure of hookworm infection.
A new compound, 4-isothiocyanato-4'-nitrodiphenylamine (C.9333-Go/CGP 4540), was tried in 39 hospitalized patients with hookworm infection, using several treatment schedules. At effective dose schedules (125 mg X 3 given 4-hourly; 250 mg X 3, 8-hourly; 1,000 mg X 3, 12-hourly), the egg reduction was 96% to 100%; the zero egg-counts were confirmed by coproculture for larvae. The compound was very well tolerated. Transient and mild side effects--giddiness, diarrhea and sweating--were observed in only three patients. No toxic effects were seen as judged by serial organ function tests, except a transient and mild asymptomatic elevation of transaminases in one patient.
D000328:Adult; D000814:Aniline Compounds / Q000627:therapeutic use*; D000969:Antinematodal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004159:Diphenylamine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006725:Hookworm Infections / Q000188:drug therapy*; D006801:Humans; D017879:Isothiocyanates; D013861:Thiocyanates / Q000009:adverse effects / Q000627:therapeutic use*
D000814:Aniline Compounds; D000969:Antinematodal Agents; D017879:Isothiocyanates; D013861:Thiocyanates; D004159:Diphenylamine; C012391:amoscanate